🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 252828108 (prev. 55910K108 )
- Market Cap
- Small Cap
- IPO
- 6/21/2018 · $15.00/share
- Previous Symbol
- MGTA (changed 9/11/2023)
- Previous Name
- Magenta Therapeutics, Inc.
Business: Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency.
Notes: May 03, 2023 -- Magenta Therapeutics, Inc. (Nasdaq: MGTA) (“Magenta”) and Dianthus Therapeutics, Inc. (“Dianthus”), a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Dianthus’ pipeline of next-generation complement inhibitors, including DNTH103 currently in a Phase 1 clinical trial. Upon completion of the merger, the combined company is expected to operate under the name Dianthus Therapeutics, Inc. and trade on the Nasdaq under the ticker symbol “DNTH”.
Company Contact
- CEO
- Marino Garcia
- CFO
- Ryan Savitz
- Headquarters
- 7 Times Square, 43rd Floor, New York, NY 10036
- Phone
- 929-999-4055
- Investor Relations
- Lyndsey Scull · 857-242-0170 · IR@dianthustx.com